LAKE FOREST, Ill. , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) (“Assertio”) today announced it has entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of holders of Assertio’s currently outstanding 2.50%

-- Reports Total Company GAAP Net Sales of $57.2 million , Total Company Non-GAAP Net Sales of $59.3 million , including Commercialization Agreement Revenues of $31.0 million -- -- Drives Continued Improvement in Operating Efficiencies as the Company  Executes on its Ongoing Transformation -- --

LAKE FOREST, Ill. , July 17, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019 , after the close of markets. Following the announcement, the Company will host a conference call

-- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance -- -- Significant Debt Reduction -- LAKE FOREST, Ill.

LAKE FOREST, Ill. , April 24, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019 , after the close of markets. Following the announcement, the Company will host a conference call

LAKE FOREST, Ill. , April 01, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that James (Jay) J. Galeota, Jr. has been appointed to the Company’s Board of Directors. Mr. Galeota most recently served as the President and Chief Operating Officer of G&W

LAKE FOREST, Ill. , March 28, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Assertio with respect to the company’s patent litigation against three filers of Abbreviated New

-- Reports Neurology Franchise Annual Net Sales of $110.3 million , at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LAKE FOREST, Ill.

LAKE FOREST, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019 , after the close of markets. Following the announcement, the Company will host a

Company Anticipates Potential Market Launch by Early 2020 LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration ( FDA ) for its 505(b)(2)